Mar 31, 2025 8:30am EDT Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
Mar 03, 2025 8:00am EST Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
Feb 14, 2025 9:00am EST Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
Feb 11, 2025 9:00am EST Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland
Jan 13, 2025 9:00am EST Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Dec 09, 2024 9:15am EST Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Nov 18, 2024 8:30am EST Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Nov 13, 2024 8:30am EST Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Nov 12, 2024 8:00am EST Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 05, 2024 8:30am EST Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
